Ottobock stock heads into Q3 test after Goldman target cut

Published on 11/11/2026 at 12:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ottobock stock is heading into its next quarterly test after Goldman Sachs cut its price target. The bank kept its Buy rating.

Goldman cuts target before quarterly update

Goldman Sachs lowered its Ottobock price target while retaining a Buy rating.
The revised target reflects a more cautious near-term view on growth and North American performance.
The upcoming third-quarter release is the next key test for revenue momentum and the company outlook.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Goldman Sachs has lowered its price target for Ottobock while keeping a Buy rating, putting the medical technology company under a closer watch ahead of its next quarterly update. MarketScreener reported on Wednesday, October 21, that analyst Richard Felton reduced the target from 88 euros to 75 euros.

Goldman takes a more cautious view

The revised target lowers Goldman's valuation framework by 13 euros, or 14.8 percent, while leaving the recommendation unchanged at Buy. The combination signals a more guarded near-term assessment rather than a withdrawal of the bank's positive medium-term stance.

Goldman expects relatively weak revenue growth in the third quarter and continues to see pressure in North America. Regional performance will therefore be central to the next company update, particularly whether weakness in that market was offset by momentum elsewhere.

Quarterly figures become the next test

Ottobock's third-quarter release is the next catalyst for investors assessing revenue momentum, regional trends and the full-year outlook. The update should show whether the company's operating trajectory has held up after the first-half performance highlighted by investor materials and whether the margin outlook remains supported.

Ottobock stock traded at 46.35 euros on Lang & Schwarz at 12:00:28 CET on Wednesday, November 11, 2026. The quote provides a live market reference as investors position for the quarterly communication, but the analyst target and the traded price reflect different measures: one is a forward valuation view, while the other is a market quotation.